Application of lymphocytes test in peripheral blood of patients with systemic sclerosis during the treatment

  • Xiang-bo MA ,
  • Xue-wu ZHANG ,
  • Ru-lin JIA ,
  • Ying GAO ,
  • Hong-jiang LIU ,
  • Yu-fang LIU ,
  • Ying-ni LI
Expand
  • 1. Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing 100044, China
    2. Department of Rheumatology and Immunology, Handan First Hospital, Handan 056002, Hebei, China
    3. Department of Endocrinology, Peking University People’s Hospital, Beijing 100044, China
    4. Department of Rheumatology and Immunology, Second Hospital of Shanxi Medical University,Taiyuan 030000, China

Received date: 2020-07-26

  Online published: 2021-08-25

Supported by

National Natural Science Foundation of China(81701614);Peking Univercity People’s Hospital Research and Development Funds(RDC2019-01)

Abstract

Objective: To explore the significance of lymphocytes in systemic sclerosis (SSc), by detecting the levels of T lymphocytes, B lymphocytes and natural killer (NK) cells, and analyzing the correlation between the lymphocytes and clinical laboratory indexes. Methods: The numbers and proportion of T, CD4+T, CD8+T, B, and NK cells were detected by flow cytometry in peripheral blood of 32 SSc patients who had taken immunosuppressive drugs and 30 healthy controls (HC). The comparison of the lymphocyte subsets in SSc with them in the HC groups, and the correlation between the lymphocytes and other clinical and laboratory indicators were analyzed by the relevant statistical analysis. Results: Compared with the HC group, the numbers of T, CD4+T, CD8+T, and NK cells in peripheral blood of SSc group,who had taken immunosuppressive drugs, were significantly decreased (P<0.05). More-over, the proportion of NK cells in peripheral blood of the SSc group was also significantly lower than that in the HC group (P=0.004). In addition, all the lymphocyte subsets were decreased in peripheral blood of more than 65% of the SSc patients who had taken immunosuppressive drugs. Compared with CD4+T normal group, the positivity of Raynaud’s phenomenon, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) was significantly increased in CD4+T reduction group, respectively (P=0.024, P<0.001, P=0.018). ESR was higher in CD8+T reduction group than CD8+T normal group (P=0.022). The prevalence of fingertip ulcer was significantly increased in B cell decrease group (P=0.019). Compared with NK cell normal group, the prevalence of fingertip ulcer was significantly increased in NK cell lower group (P=0.033), IgM was remarkablely decreased yet (P=0.049). The correlation analysis showed that ESR was negatively correlated with the counts of T lymphocytes (r=-0.455, P=0.009), CD4+T lymphocytes (r=-0.416, P=0.018), CD8+T lymphocytes (r=-0.430, P=0.014), B cells (r=-0.366, P=0.039). Conclusion: The number of CD4+T, CD8+T, B, and NK cells significantly decreased in peripheral blood of SSc patients who had used immunosuppressive drugs, some lymphocyte subsets might be related with Raynaud’s phenomenon and fingertip ulcer, and reflected the disease activity by negatively correlated with ESR and CRP; the numbers of lymphocyte subsets in peripheral blood should be detected regularly in SSc patients who had taken immunosuppressive drugs.

Cite this article

Xiang-bo MA , Xue-wu ZHANG , Ru-lin JIA , Ying GAO , Hong-jiang LIU , Yu-fang LIU , Ying-ni LI . Application of lymphocytes test in peripheral blood of patients with systemic sclerosis during the treatment[J]. Journal of Peking University(Health Sciences), 2021 , 53(4) : 721 -727 . DOI: 10.19723/j.issn.1671-167X.2021.04.017

References

[1] Denton CP, Khanna D. Systemic sclerosis [J]. Lancet, 2017, 390(10103):1685-1699.
[2] Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: A study from the EULAR Scleroderma Trials and Research (EUSTAR) database [J]. Ann Rheum Dis, 2010, 69(10):1809-1815.
[3] van den Hoogen F, Khanna D, Fransen J, et al. Classification criteria for systemic sclerosis: An American college of rheumatology/European league against rheumatism collaborative initiative [J]. Ann Rheum Dis, 2013, 72(11):1747-1755.
[4] Bossini-Castillo L, Martin JE, Broen J, et al. Confirmation of TNIP1 but not RHOB and PSORSICI as systemic sclerosis risk factors in a large independent replication study [J]. Ann Rheum Dis, 2013, 72(4):602-607.
[5] Marou E, Liaskos C, Efthymiou G, et al. Increased immunoreactivity against human cytomegalovirus UL83 in systemic sclerosis [J]. Clin Exp Rheumatol, 2017, 35(Suppl 106):31-34.
[6] Marie I, Gehanno JF, Bubenheim M, et al. Systemic sclerosis and exposure to heavy metals: A case control study of 100 patiens and 300 controls [J]. Autoimmun Rev, 2017, 16(3):223-230.
[7] Borghini A, Poscia A, Bosello S, et al. Environmental pollution by benzene and PM10 and clinical manifestation of systemic sclerosis:A correlation study [J]. Int J Environ Res Public Health, 2017, 14(11):1297.
[8] Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer [J]. Science, 2014, 343(6167):152-157.
[9] Cipriani P, Marrelli A, Liakouli V, et al. Cellular players in angiogenesis during the course of systemic sclerosis [J]. Autoimmu Rev, 2011, 10(10):641-646.
[10] Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR scleroderma trials and research group database [J]. Ann Rheum Dis, 2007, 66(6):754-763.
[11] Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: Evidence that systemic sclerosis is a vascular disease [J]. Arthritis Rheum, 2013, 65(8):1953-1962.
[12] Liu M, Wu W, Sun X, et al. New insights into CD4+ T cell abnormalities in systemic sclerosis [J]. Cytokine Growth Factor Rev, 2016, 28:31-36.
[13] Yang XQ, Yang J, Xing XJ, et al. Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction [J]. Arthritis Res Ther, 2014, 16(1):R4.
[14] Yoshizaki A, Yanaba K, Iwata Y, et al. Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model [J]. Immunology, 2010, 185(4):2502-2515.
[15] Bogoch ER, Gross DK. Surgery of the hand in patients with systemic sclerosis: outcomes and considerations [J]. Rheumatology, 2005, 32(4):642-648.
[16] Sakkas LI, Boqdanos DP. Systemic sclerosis: new evidence reenforces the role of B cells [J]. Autoimmu Rev, 2016, 15(2):155-161.
[17] Yoshizaki A. Pathogenic roles of B lymphocytes in systemic sclerosis [J]. Immunol Lett, 2018, 195:76-82.
[18] Wang MH, Chandra M. B-cells in systemic sclerosis: Emerging evidence from genetics to phenotypes [J]. Curr Opin Rheumatol, 2015, 27(6):537-541.
[19] Dumoitier N, Chaigne B, Régent A, et al. Scleroderma peripheral B lymphocytes secrete interleukin-6 and transforming growth factor β and activate fibroblasts [J]. Arthritis Rheumatol, 2017, 69(5):1078-1089.
[20] Katz P, Mitchell SR, Cupps TR, et al. Suppression of B cell responses by natural killer cells is mediated through direct effects on T cells [J]. Cell Immunol, 1989, 119(1):130-142.
[21] Fullard N, O’Reilly S. Role of innate immune system in systemic sclerosis [J]. Semin Immunopathol, 2015, 37(5):511-517.
[22] Cossu M, van Bon L, Nierkens S, et al. The magnitude of cytokine production by stimulated CD56+ cells is associated with early stages of systemic sclerosis [J]. Clin Immunol, 2016, 173:76-80.
Outlines

/